Published in J Clin Oncol on November 01, 1999
OGX-427 in Castration Resistant Prostate Cancer Patients | NCT01120470
Ketoconazole Plus Docetaxel to Treat Prostate Cancer | NCT00032825
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer | NCT04019964
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol (2012) 3.73
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol (2009) 3.51
Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol (2009) 2.56
Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol (2012) 2.45
Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res (2005) 2.44
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol (2013) 2.35
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer (2008) 2.35
Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol (2009) 2.27
A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol (2009) 2.26
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res (2011) 2.23
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res (2006) 2.20
Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res (2011) 2.17
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol (2011) 2.14
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res (2011) 2.01
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res (2005) 1.97
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood (2008) 1.81
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer (2008) 1.73
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol (2009) 1.67
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res (2011) 1.61
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2008) 1.56
Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med (2008) 1.56
The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol (2011) 1.55
Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res (2013) 1.53
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res (2013) 1.51
A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia (2007) 1.50
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer (2011) 1.49
Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer (2003) 1.46
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res (2009) 1.46
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? Br J Cancer (2009) 1.44
Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One (2011) 1.38
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs (2007) 1.37
Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res (2010) 1.37
An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res (2009) 1.36
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer (2009) 1.33
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer (2007) 1.33
An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer (2010) 1.32
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.29
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs (2009) 1.26
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer (2010) 1.23
C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med (2011) 1.23
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol (2016) 1.21
Membrane glycoproteins associated with breast tumor cell progression identified by a lectin affinity approach. J Proteome Res (2008) 1.21
A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. Am J Transl Res (2010) 1.19
Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res (2010) 1.18
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer (2009) 1.17
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol Immunother (2010) 1.17
Effective incorporation of biomarkers into phase II trials. Clin Cancer Res (2009) 1.17
A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol. Br J Cancer (2011) 1.17
Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. Urology (2008) 1.15
A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. Br J Cancer (2008) 1.15
Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clin Cancer Res (2009) 1.13
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann Oncol (2011) 1.11
Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol (2008) 1.08
Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding. Br J Cancer (2005) 1.07
Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology (2011) 1.06
Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging (2013) 1.05
(11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. Eur J Nucl Med Mol Imaging (2015) 1.04
Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer (2013) 1.04
Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. PLoS One (2011) 1.03
Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med (2013) 1.02
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours. Br J Cancer (2008) 1.02
Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br J Cancer (2009) 1.01
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs (2007) 1.01
Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther (2010) 1.00
A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer (2007) 1.00
Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res (2013) 1.00
A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer (2007) 0.99
An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer (2003) 0.98
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer (2002) 0.98
Suramin's development: what did we learn? Invest New Drugs (2002) 0.97
Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. Cancer Immunol Res (2015) 0.97
Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients. Asian J Androl (2009) 0.96
A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. Can Urol Assoc J (2009) 0.96
Prognosis Related to Metastatic Burden Measured by ¹⁸F-Fluorocholine PET/CT in Castration-Resistant Prostate Cancer. J Nucl Med (2014) 0.95
Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer Lett (2012) 0.95
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. Invest New Drugs (2011) 0.95
Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study. J Clin Oncol (2009) 0.95
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs (2010) 0.95
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clin Cancer Res (2010) 0.95
Detection of circulating tumor cells in cancers of biliary origin. J Gastrointest Oncol (2012) 0.94
Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy. J Interferon Cytokine Res (2009) 0.94
Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study. Trials (2012) 0.94
Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Br J Cancer (2009) 0.93
Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol (2012) 0.93
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. Br J Cancer (2004) 0.93
Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol (2005) 0.93
(11)C-acetate PET imaging in prostate cancer. Eur J Nucl Med Mol Imaging (2007) 0.93
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers. Clin Cancer Res (2014) 0.92
Prostate cancer: PSA as an intermediate end point in clinical trials. Nat Rev Urol (2009) 0.92
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 13.90
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res (2004) 9.18
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med (1998) 6.84
Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature (1985) 6.41
Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med (1999) 6.21
An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes. Mol Cell Biol (1996) 5.74
Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics (2001) 5.58
Evidence for autolysin-mediated primary attachment of Staphylococcus epidermidis to a polystyrene surface. Mol Microbiol (1997) 5.47
Requirement for c-ras proteins during viral oncogene transformation. Nature (1986) 5.24
The Salmonella invasin SipB induces macrophage apoptosis by binding to caspase-1. Proc Natl Acad Sci U S A (1999) 5.17
Studies on an acetate-fermenting strain of Methanosarcina. Appl Environ Microbiol (1978) 4.75
Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst (1997) 4.60
Interactive memory systems in the human brain. Nature (2001) 4.53
Trends in reported incidence of primary malignant brain tumors in children in the United States. J Natl Cancer Inst (1998) 4.32
STUDIES ON THE MECHANISM OF RECOVERY IN PNEUMOCOCCAL PNEUMONIA : IV. THE MECHANISM OF PHAGOCYTOSIS IN THE ABSENCE OF ANTIBODY. J Exp Med (1946) 4.20
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol (1999) 4.12
Direct text entry in electronic progress notes. An evaluation of input errors. Methods Inf Med (2003) 4.00
Cloning and sequencing of the metallothioprotein beta-lactamase II gene of Bacillus cereus 569/H in Escherichia coli. J Bacteriol (1985) 3.95
Hypersensitivity reactions from taxol. J Clin Oncol (1990) 3.83
Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial. Pediatrics (1994) 3.74
Growth and methanogenesis by Methanosarcina strain 227 on acetate and methanol. Appl Environ Microbiol (1978) 3.70
Phenotype of mice lacking functional Deleted in colorectal cancer (Dcc) gene. Nature (1997) 3.57
European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol (2009) 3.56
Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol (1998) 3.38
Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci U S A (1998) 3.35
A bacterial invasin induces macrophage apoptosis by binding directly to ICE. EMBO J (1996) 3.16
Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med (1999) 3.11
Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst (1998) 3.08
Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol (1992) 3.00
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res (1999) 2.96
Accumulation of glyceride-containing precursor of the outer membrane lipoprotein in the cytoplasmic membrane of Escherichia coli treated with globomycin. J Biol Chem (1980) 2.91
Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med (2001) 2.89
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet (2001) 2.85
An unbiased signal-to-noise ratio measure for magnetic resonance images. Med Phys (1993) 2.83
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol (2001) 2.73
Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993 through December 1994. Am J Obstet Gynecol (1998) 2.72
Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics (2000) 2.71
Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr (1996) 2.70
Biological and Immunological Properties of Encapsulated Strains of Staphylococcus aureus from Human Sources. Infect Immun (1970) 2.68
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol (1996) 2.67
Assessment of the risk of the respiratory-distress syndrome by a rapid test for surfactant in amniotic fluid. N Engl J Med (1972) 2.56
Prenatal and intrapartum high-risk screening. I. Prediction of the high-rish neonate. Am J Obstet Gynecol (1973) 2.56
Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst (1997) 2.51
Child abuse referral warning. Br Dent J (2006) 2.44
OATP1B1 polymorphism as a determinant of erythromycin disposition. Clin Pharmacol Ther (2012) 2.43
Human midbrain sensitivity to cognitive feedback and uncertainty during classification learning. J Neurophysiol (2004) 2.41
Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med (1988) 2.40
Heat labile opsonins to pneumococcus. II. Involvement of C3 and C5. J Exp Med (1969) 2.38
Myristoylation is important at multiple stages in poliovirus assembly. J Virol (1991) 2.36
Isolation and characterization of the beta-ketoacyl-acyl carrier protein synthase III gene (fabH) from Escherichia coli K-12. J Biol Chem (1992) 2.35
Longitudinal growth of hospitalized very low birth weight infants. Pediatrics (1999) 2.29
Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol (2009) 2.27
Heat labile opsonins to pneumococcus. I. Participation of complement. J Exp Med (1969) 2.24
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A (2000) 2.23
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol (2000) 2.22
Significance of blood pressure in infancy. Familial aggregation and predictive effect on later blood pressure. Hypertension (1985) 2.20
Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. The National Institute of Child Health and Human Development Neonatal Research Network. Pediatr Infect Dis J (1998) 2.18
Expression profiling of the maize flavonoid pathway genes controlled by estradiol-inducible transcription factors CRC and P. Plant Cell (2000) 2.17
Topical nitroglycerin ointment as an aid to insertion of peripheral venous catheters in neonates. J Pediatr (1989) 2.15
A gain-of-function mutation in the sodium channel gene Scn2a results in seizures and behavioral abnormalities. Neuroscience (2001) 2.14
Heterologously expressed Staphylococcus aureus fibronectin-binding proteins are sufficient for invasion of host cells. Infect Immun (2000) 2.11
Accuracy and reliability of glucose reflectance meters in the high-risk neonate. J Pediatr (1989) 2.10
Relation of Surface Phagocytosis to the Fibrinous Character of Acute Bacterial Exudates. Science (1949) 2.08
Representation of older patients in cancer treatment trials. Cancer (1994) 2.06
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res (2001) 2.05
The 1997 AAP guidelines for prevention of early-onset group B streptococcal disease. American Academy of Pediatrics. Pediatrics (1997) 2.04
Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res (1996) 2.04
More is not always better: a case for low-dose leucovorin. J Clin Oncol (1993) 2.03
Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res (1999) 2.02
Child abuse referral warning. Br Dent J (2006) 2.01
Applications of free living plant growth-promoting rhizobacteria. Antonie Van Leeuwenhoek (2004) 1.99
'The metabolism of tumours': 70 years later. Novartis Found Symp (2001) 1.99
Prevalence rates and correlates of psychiatric disorders among preschool children. J Am Acad Child Adolesc Psychiatry (1996) 1.98
Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest (1994) 1.97
Family-environment risk factors for attention-deficit hyperactivity disorder. A test of Rutter's indicators of adversity. Arch Gen Psychiatry (1995) 1.97
Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol (1996) 1.95
Sphincter-sparing treatment for distal rectal adenocarcinoma. Ann Surg Oncol (1999) 1.95
Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust (1996) 1.94
Characterization of new membrane lipoproteins and their precursors of Escherichia coli. J Biol Chem (1981) 1.94
The impact of disease severity on the informed consent process in clinical research. Am J Med (1996) 1.94
Religious circumcision: a Muslim view. BJU Int (1999) 1.93
Intercellular Surface Phagocytosis. Science (1947) 1.92
Challenges to implementation of the new Coroners' (Amendment) Rules 2005: experience from a tertiary paediatric pathology centre. Med Sci Law (2007) 1.92
Volume-outcome relation for physicians and hospitals performing angioplasty for acute myocardial infarction in New York state. Circulation (2001) 1.91
Inaccuracy of Ballard scores before 28 weeks' gestation. National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr (1999) 1.91
Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate. Oncogene (2010) 1.87
Early-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr (1996) 1.87
The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB. J Exp Med (1996) 1.87
Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med (2001) 1.85
Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res (1988) 1.84
The fate of ribosomes in Escherichia coli cells starved for a carbon source. J Biol Chem (1975) 1.83
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res (1996) 1.82
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol (2001) 1.81
Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology (1999) 1.80